JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robbins, R. J.
Right arrow Articles by Tuttle, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robbins, R. J.
Right arrow Articles by Tuttle, R. M.

A Retrospective Review of the Effectiveness of Recombinant Human TSH as a Preparation for Radioiodine Thyroid Remnant Ablation

Richard J. Robbins, MD1, Steven M. Larson, MD2, Naina Sinha, MD1, Ashok Shaha, MD3, Chaitanya Divgi, MD2, Keith S. Pentlow, PhD2, Ronald Ghossein, MD4 and R. Michael Tuttle, MD1

1 Endocrinology Service, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan-Kettering Cancer Center, New York, New York
2 Nuclear Medicine Service, Department of Radiology, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan-Kettering Cancer Center, New York, New York
3 Head and Neck Surgery Service, Department of Surgery, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan-Kettering Cancer Center, New York, New York
4 Division of Molecular Pathology, Department of Pathology, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan-Kettering Cancer Center, New York, New York



View larger version (18K):

[in a new window]
  		FIGURE 1. Overview of diagnostic (Dx) and therapy time schedules. 131I-Dx, diagnostic radioiodine administration; 131I-Rx, therapeutic administration of 131I; RxWBS, whole-body scan after therapy. Letters in horizontal row of boxes indicate days of week.

 


View larger version (21K):

[in a new window]
  		FIGURE 2. RRA rates in 2 groups: THW and rhTSH. Numbers above bars indicate exact percentage obtained for each category.

 


View larger version (22K):

[in a new window]
  		FIGURE 3. Comparison of amount of 131I administered and final clinical outcome. (A) Group 1. (B) Group 2.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2002 by the Society of Nuclear Medicine.